Today: 8 February 2026
Subscribe

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Marvell Technology (MRVL) Stock Tumbles on Amazon and Microsoft Fears as AI Growth Story Gets Re‑Priced

Marvell Technology (MRVL) Stock Tumbles on Amazon and Microsoft Fears as AI Growth Story Gets Re‑Priced

Updated: December 8, 2025 Marvell Technology, Inc. (NASDAQ: MRVL) just got a harsh reminder that being an “AI infrastructure winner” doesn’t make you invincible. On Monday, December 8, Marvell stock fell sharply after a high‑profile analyst downgrade tied to possible custom‑chip design losses at Amazon Web Services and fresh worries that Microsoft may shift some custom silicon work to Broadcom. Intraday, MRVL dropped more than 10% before recovering part of the loss, trading in a roughly $88.9–$92.6 range — about 7% below Friday’s close of $98.91.StockAnalysis+2Investing.com+2 Paradoxically, on the very same day, Zacks upgraded Marvell to its top “Strong Buy”
8 December 2025
···
Air Products Stock Plunges to 52‑Week Low on Yara Hydrogen Deal – What It Means for APD Investors Now

Air Products Stock Plunges to 52‑Week Low on Yara Hydrogen Deal – What It Means for APD Investors Now

Air Products and Chemicals, Inc. (NYSE: APD) just had a rough session.On December 8, 2025, the stock dropped roughly 9–10%, hit a new 52‑week low around $235–236, and briefly became the worst performer in the S&P 500 after the company announced advanced partnership talks with Yara International on major low‑emission ammonia projects in the U.S. and Saudi Arabia. MarketScreener+1 At the close, APD was around $236 per share, down from a prior close near $260.69, and about 25% below its level a year ago. Investing.com Below is a breakdown of what changed today, what’s driving the sell‑off, and how Wall
8 December 2025
··
Legend Biotech (LEGN) Stock Hits 52‑Week Low After UBS Cut: December 8, 2025 News, Outlook and Forecast

Legend Biotech (LEGN) Stock Hits 52‑Week Low After UBS Cut: December 8, 2025 News, Outlook and Forecast

Legend Biotech Corp. (NASDAQ: LEGN) shares are under heavy pressure on December 8, 2025, trading in the mid‑$20s and touching a new 52‑week low around $25.66 during the session. The slide comes despite strong clinical momentum for its flagship CAR‑T therapy CARVYKTI® and robust revenue growth, as investors react to valuation resets and ongoing concerns about profitability and cash flow. Investing.com+1 This article rounds up the key news and analysis on Legend Biotech stock from December 8, 2025 and the days immediately preceding it, and looks at what Wall Street expects next for LEGN. Disclaimer: This article is for information
8 December 2025
··
Warby Parker (WRBY) Stock Soars on Google AI Glasses Timeline: Price Action, Earnings and 2026 Forecasts as of December 8, 2025

Warby Parker (WRBY) Stock Soars on Google AI Glasses Timeline: Price Action, Earnings and 2026 Forecasts as of December 8, 2025

Updated December 8, 2025 Warby Parker Inc. (NYSE: WRBY) is suddenly trading like an AI story, not just an eyewear retailer. Shares jumped around 15% on Monday, December 8, 2025, with the stock recently changing hands near $21.51, after fresh disclosures and media coverage confirmed that Google and Warby Parker plan to launch AI-powered smart glasses in 2026 as part of the Android XR platform.GuruFocus+1 The surge caps a dramatic rebound from autumn lows, coming just weeks after a mixed reaction to the company’s Q3 2025 earnings, where Warby Parker delivered strong growth and a return to profitability but narrowly
8 December 2025
··
Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is finishing 2025 with the kind of momentum small-molecule biotechs daydream about. On 8 December 2025, the RNA interference (RNAi) specialist climbed to a new 52‑week high near $69 per share after the company announced it had dosed the first subjects in its Alzheimer’s disease trial ARO‑MAPT and highlighted a string of recent FDA victories and deal-driven cash inflows. Arrowhead Pharmaceuticals, Inc.+2MarketBeat+2 The rally caps a stunning year in which Arrowhead stock has delivered a year‑to‑date return of roughly 270% and a one‑year gain in the 160–200% range, depending on the data provider, vastly outpacing
8 December 2025
·
Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025

Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025

Nurix Therapeutics, Inc. (NASDAQ: NRIX) is back in the spotlight. On December 8, 2025, the biotech stock surged roughly 20% intraday after the company released new Phase 1 data for its Bruton’s tyrosine kinase (BTK) degrader bexobrutideg (NX‑5948) in blood cancers at the American Society of Hematology (ASH) Annual Meeting and scheduled a corporate webcast for this evening. MarketBeat+3GlobeNewswire+3GlobeNewswire+3 The rally comes barely two months after Nurix posted a weak third quarter and executed a large equity raise, underscoring how heavily sentiment in this name is tied to the clinical trajectory of its degrader pipeline. ChartMill+2StockAnalysis+2 NRIX stock today: price
8 December 2025
··
Carvana (CVNA) Soars on S&P 500 Inclusion: Latest News, Stock Forecast and Analysis as of December 8, 2025

Carvana (CVNA) Soars on S&P 500 Inclusion: Latest News, Stock Forecast and Analysis as of December 8, 2025

Carvana Co. (NYSE: CVNA) is back in the spotlight. On Monday, December 8, 2025, the online used-car retailer’s shares surged again after S&P Dow Jones Indices confirmed that Carvana will join the benchmark S&P 500 index on December 22, 2025. The stock traded around $454 in late session, up roughly 14% on the day and near record highs, capping a year in which the stock has gained well over 100% and staged one of the most dramatic recoveries in recent market history. Reuters According to Reuters, Carvana’s market value has swelled to roughly $87 billion, now exceeding both Ford and
8 December 2025
·
Kymera Therapeutics (KYMR) Stock Soars on KT‑621 Eczema Data: What December 8, 2025 Means for Investors

Kymera Therapeutics (KYMR) Stock Soars on KT‑621 Eczema Data: What December 8, 2025 Means for Investors

Kymera Therapeutics, Inc. (NASDAQ: KYMR) delivered one of the biggest biotech moves on Wall Street today. On Monday, December 8, 2025, Kymera stock surged more than 40% intraday, trading around $96 late in the session after touching an intraday high above $100, on volume far above normal. MarketBeat The catalyst: very strong Phase 1b data for KT‑621, a once‑daily oral STAT6 degrader for atopic dermatitis (eczema) and broader Type 2 inflammatory diseases. GlobeNewswire Below is a full breakdown of today’s news, analyst reactions, and what the move could mean for Kymera stock in the months ahead. Kymera Therapeutics Stock Rockets
8 December 2025
·
Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough – What the New Data and Wall Street Forecasts Signal

Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough – What the New Data and Wall Street Forecasts Signal

Published: December 8, 2025 WVE stock more than doubles on massive volume Wave Life Sciences Ltd. (NASDAQ: WVE) staged a spectacular rally on Monday after unveiling positive interim data from its Phase 1 INLIGHT trial for obesity drug candidate WVE‑007. Shares surged from a close of $7.49 on Friday, December 5 to intraday levels around $17–18, a gain in the range of 120%–140% and a new multi‑year high. Yahoo Finance+2Investing.com+2 Trading volume blew out to more than 100 million shares, roughly 40 times the stock’s recent average daily volume of about 2.5 million, underscoring intense speculative interest and likely short
8 December 2025
Confluent (CFLT) Soars on IBM’s $11 Billion Takeover: Deal Terms, Stock Outlook and Analyst Forecasts After December 8, 2025 Rally

Confluent (CFLT) Soars on IBM’s $11 Billion Takeover: Deal Terms, Stock Outlook and Analyst Forecasts After December 8, 2025 Rally

Confluent, Inc. (NASDAQ: CFLT) has suddenly shifted from a high-growth data‑infrastructure story to a classic M&A arbitrage play. On December 8, 2025, IBM and Confluent announced a definitive agreement under which IBM will acquire all outstanding Confluent shares for $31 in cash, valuing the data‑streaming specialist at around $11 billion enterprise value.IBM Newsroom+2ABC News+2 The news sent CFLT stock up roughly 29% in today’s session, as traders rapidly repriced the shares toward the proposed cash buyout price.MarketBeat Confluent Stock News Today: IBM Confirms $11 Billion Cash Deal IBM and Confluent jointly announced that they have entered into a definitive merger
8 December 2025
·
Banco Bradesco (BBD) Stock on December 8, 2025: Is the Post‑Earnings Sell‑Off a Buying Opportunity?

Banco Bradesco (BBD) Stock on December 8, 2025: Is the Post‑Earnings Sell‑Off a Buying Opportunity?

Published: December 8, 2025 – Informational article, not investment advice. Key points Banco Bradesco stock today: price action and context Banco Bradesco S.A., Brazil’s second‑largest private bank and a diversified financial and insurance group, is back under the market microscope. Its NYSE‑listed ADRs trade around $3.35 on December 8, 2025, up slightly on the day and sitting close to the upper half of their 52‑week range between $1.84 and $3.77. Investing The calm today follows a stormy Friday: Despite this pullback, BBD has had a powerful 2025: In other words, the recent fall is happening after a major run‑up, not
8 December 2025
·
Spirit AeroSystems (SPR) Stock on December 8, 2025: Boeing Takeover, NYSE Delisting and What Shareholders Get

Spirit AeroSystems (SPR) Stock on December 8, 2025: Boeing Takeover, NYSE Delisting and What Shareholders Get

Spirit AeroSystems Holdings, Inc. (NYSE: SPR) has effectively reached the end of its life as a standalone public stock. On December 8, 2025, Boeing officially completed its acquisition of Spirit AeroSystems, halted trading in SPR, and kicked off the process to delist the shares from the New York Stock Exchange (NYSE).Boeing Investors+1 For anyone who owns SPR, tracks aerospace stocks, or just likes untangling big industrial deals, this is a pivotal day. Key takeaways for Spirit AeroSystems (SPR) on December 8, 2025 Let’s unpack what actually happened today, what it means for SPR stockholders, and how this reshapes the Boeing–Airbus–Spirit
8 December 2025
···
Rivian Stock on December 8, 2025: Downgrade, Recall and R2 Hopes – What RIVN Investors Need to Know

Rivian Stock on December 8, 2025: Downgrade, Recall and R2 Hopes – What RIVN Investors Need to Know

Rivian Automotive, Inc. (NASDAQ: RIVN) is back in the market spotlight today, and not in a quiet way. As of Monday afternoon, Rivian shares were trading around $17.30, down roughly 3–5% on the day, with intraday trading between about $17.05 and $17.70. That pullback comes after a strong rally from the April 2024 low of about $8.26 and a 12‑month gain in the high 30% range, even though the stock is still down roughly 90% from its 2021 peak near $172.FinancialContent+1 Today’s move is being driven by a high‑profile downgrade from Morgan Stanley, a recall of nearly 35,000 delivery vans,
8 December 2025
·
UiPath (PATH) Stock Soars After First GAAP Profit: Can the AI Automation Rally Last? – December 8, 2025

UiPath (PATH) Stock Soars After First GAAP Profit: Can the AI Automation Rally Last? – December 8, 2025

UiPath Inc. (NYSE: PATH) has quickly moved back onto traders’ radar screens. After delivering its first GAAP‑profitable quarter and raising guidance, the automation specialist’s shares have surged to fresh 52‑week highs and are now trading above where most Wall Street analysts think the stock is worth. As of the close on December 8, 2025, UiPath stock changes hands around $19.12, up roughly 2–3% on the day, with an intraday range between $18.75 and $19.83 and heavy trading volume of nearly 19 million shares. Zacks notes the stock has climbed about 30% over the past month, handily outperforming the broader market.Zacks
8 December 2025
··
Structure Therapeutics (GPCR) Stock Soars on Obesity Pill Data: Latest News, Analyst Forecasts and 2026 Outlook (December 8, 2025)

Structure Therapeutics (GPCR) Stock Soars on Obesity Pill Data: Latest News, Analyst Forecasts and 2026 Outlook (December 8, 2025)

Structure Therapeutics Inc. (NASDAQ: GPCR) just turned a long‑anticipated clinical readout into a full‑blown stock market event. On Monday, December 8, 2025, the company released positive topline data from its ACCESS program for aleniglipron (GSBR‑1290), a once‑daily oral GLP‑1 receptor agonist for obesity. The market response was immediate: GPCR closed at $69.46, up about 101% on the day, after trading between $24.83 and an intraday high of $94.90. That move vaulted Structure into the front rank of the oral obesity drug race and forced investors, analysts and competitors to update their models in real time. Who is Structure Therapeutics and
8 December 2025
···
Bitcoin Nears $92K as Fed Rate-Cut Bets and XRP ETF Boom Lift Crypto – BTC, ETH, XRP and Solana Price Outlook for December 8, 2025

Bitcoin Nears $92K as Fed Rate-Cut Bets and XRP ETF Boom Lift Crypto – BTC, ETH, XRP and Solana Price Outlook for December 8, 2025

The new trading week has opened with a solid green wave across the crypto market. On Monday, December 8, 2025, Bitcoin, Ethereum, XRP and Solana are all pushing higher as traders lean into Federal Reserve rate‑cut expectations and renewed appetite for crypto exchange‑traded products (ETPs and ETFs). CryptoRank+1 Below is a deep dive into what’s driving today’s move, how the key majors are positioned, and the levels traders are watching next. Key takeaways Market snapshot: A green Monday for digital assets According to market data aggregated by Cryptonews and CryptoRank, the total cryptocurrency market capitalization has climbed roughly 2.2% today
8 December 2025
··
Opendoor Technologies (OPEN) Stock Today: Meme Rally, AI Pivot and 2026 Forecasts – December 8, 2025

Opendoor Technologies (OPEN) Stock Today: Meme Rally, AI Pivot and 2026 Forecasts – December 8, 2025

Opendoor Technologies Inc. (NASDAQ: OPEN) has turned into one of 2025’s most dramatic “story stocks.” After starting the year near $1.60, the digital home‑flipping platform now trades a little above $7 per share, a gain of more than 300% year to date, despite still‑sizeable losses and fresh dilution. MarketBeat At the same time, Wall Street’s average 12‑month price targets cluster between $1.70 and $2.90, implying large downside from current levels. Nasdaq+3MarketBeat+3StockAnalysis+3 Here’s a detailed look at where Opendoor stands as of December 8, 2025 – including the latest news, earnings, AI turnaround plan, warrant dividend, and what analysts and technical
8 December 2025
···
D-Wave Quantum (QBTS) Stock on December 8, 2025: Government Pivot, Qubits 2026 and Bubble Warnings Collide

D-Wave Quantum (QBTS) Stock on December 8, 2025: Government Pivot, Qubits 2026 and Bubble Warnings Collide

D-Wave Quantum Inc. (NYSE: QBTS) is closing out 2025 exactly the way it spent the year: at the center of the most speculative corner of the AI ecosystem. As of intraday trading on December 8, QBTS is changing hands around the high‑$20s (about $28), up more than 3% on the day. The stock has surged from roughly $2.50 at its 52‑week low to as high as $46.75, giving D-Wave a market capitalization near $9.7 billion despite still‑modest revenue and persistent losses. Webull+1 Today’s headlines add more fuel to the debate over whether D-Wave is a breakthrough quantum leader being re‑rated
8 December 2025
Canada’s F‑35 Crossroads: Quebec Maintenance Hub, Leaked Scorecard and a Last‑Minute Gripen Push

Canada’s F‑35 Crossroads: Quebec Maintenance Hub, Leaked Scorecard and a Last‑Minute Gripen Push

Canada’s long‑running fighter jet saga has erupted into a full‑blown political and industrial showdown as of December 8, 2025. A leaked Department of National Defence (DND) scoring chart strongly favoring the U.S.‑made F‑35, an aggressive push to turn Mirabel, Quebec into a major F‑35 maintenance hub, and a fresh wave of opinion pieces and lobbying on both sides of the F‑35–vs–Gripen debate are all converging just as Prime Minister Mark Carney edges toward a decision on the country’s next‑generation fighter fleet. SSBCrack News+3National Security Journal+3WLS 890 AM+3 At stake: Canada’s air defence for the next 40 years, tens of thousands
8 December 2025
··
Netflix (NFLX) Stock on December 8, 2025: Warner Bros Mega-Deal, Trump Scrutiny and 2026 Forecasts Explained

Netflix (NFLX) Stock on December 8, 2025: Warner Bros Mega-Deal, Trump Scrutiny and 2026 Forecasts Explained

Updated: December 8, 2025 Netflix Stock Today: Volatile Trading Around the Warner Bros Deal Netflix, Inc. (NASDAQ: NFLX) spent Monday trading under pressure as investors digested a flurry of headlines about its $72 billion bid for Warner Bros. Discovery’s studio and streaming assets and a surprise hostile counter-offer from Paramount Skydance. By early afternoon U.S. time, Netflix shares were changing hands at around $96, down roughly 4% from Friday’s close and about 8–10% below pre-deal levels, according to real‑time quote data and recent analyst commentary. Parameter The stock remains sharply higher year‑to‑date but has surrendered a chunk of its recent
8 December 2025
··
1 … 454 455 456 457 458 … 535

Stock Market Today

Abbott stock price: what to watch Monday after FDA Libre recall update, insider buy

Abbott stock price: what to watch Monday after FDA Libre recall update, insider buy

8 February 2026
New York, Feb 7, 2026, 17:35 EST — Market closed. Abbott Laboratories (ABT) shares rose 1.6% to $110.83 on Friday, extending a second straight day of gains. It trailed a broader rally in which the S&P 500 climbed 1.97% and the Dow gained 2.47%, and it remains 21.53% below its 52-week high of $141.23, with 9.9 million shares changing hands versus a 50-day average of 8.9 million. (MarketWatch) U.S. markets are shut on Saturday, leaving investors a weekend to focus on regulation rather than price action. The Food and Drug Administration updated a Class I recall notice — its most
Verizon stock snaps seven-day winning streak — what to watch for VZ into the new week

Verizon stock snaps seven-day winning streak — what to watch for VZ into the new week

8 February 2026
Verizon shares fell 1.7% to $46.31 on Friday, ending a seven-day rally and lagging a broad market rebound. The drop follows a leadership shakeup in the consumer unit, with Sowmyanarayan Sampath stepping down and Alfonso Villanueva named interim chief. Investors await delayed U.S. jobs and inflation data next week, which could affect rate-sensitive stocks.
Go toTop